Related Experiment Video
Updated: Jun 16, 2026
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan
L E M de Wijs1, R F T Fujimoto2, E R Andrinopoulou3
1Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Background:
Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking.
Objectives:
To investigate the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands and Japan over 80 weeks of treatment.
Methods:
A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes over time.
Results:
We found statistically significant differences in sex, disease onset, body mass index and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23·8 vs. 14·8), while baseline Patient-Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating 'mild disease' (EASI < 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan.
Conclusions:
Dupilumab showed significant, comparable and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients.
Related Concept Videos
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:13Bioequivalence studies: Biowaivers